Stay updated on XM02 vs. Filgrastim + Plerixafor in Stem Cell Mobilization Clinical Trial
Sign up to get notified when there's something new on the XM02 vs. Filgrastim + Plerixafor in Stem Cell Mobilization Clinical Trial page.

Latest updates to the XM02 vs. Filgrastim + Plerixafor in Stem Cell Mobilization Clinical Trial page
- Check2 days agoChange DetectedThe page now displays a 403 Forbidden error instead of the study record content, indicating the study page is currently inaccessible. This prevents viewing the study details and related navigation until access is restored.SummaryDifference19%

- Check9 days agoChange DetectedThe page shows a new revision label, indicating the study record version has been updated from v3.6.6 to v3.7.0. This appears to be an administrative version update rather than a change to study content.SummaryDifference0.1%

- Check16 days agoNo Change Detected
- Check24 days agoChange DetectedThe page's revision label updated from v3.6.5 to v3.6.6, indicating a newer version of the page; substantive study details appear unchanged.SummaryDifference0.1%

- Check45 days agoChange DetectedThe page shows a new Revision: v3.6.5, replacing the previous v3.6.4. This indicates a small template/system update and does not modify the study details displayed on the page.SummaryDifference0.1%

- Check66 days agoChange DetectedThe page now shows a new revision tag (v3.6.4) replacing the previous (v3.6.3), indicating a small update to the site or page. It does not imply changes to the study details or eligibility information.SummaryDifference0.1%

- Check82 days agoChange DetectedStem Cells was added to the page's terminology to reflect the study focus, and the page revision tag was updated to v3.6.3 (replacing v3.6.2).SummaryDifference0.1%

Stay in the know with updates to XM02 vs. Filgrastim + Plerixafor in Stem Cell Mobilization Clinical Trial
Enter your email address, and we'll notify you when there's something new on the XM02 vs. Filgrastim + Plerixafor in Stem Cell Mobilization Clinical Trial page.